Control Bionics Limited (ASX:CBL)

Market Cap	25.13M +95.5%
Revenue (ttm)	6.07M +14.9%
Net Income	-6.50M
EPS	-0.02
Shares Out	411.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117,295
Average Volume	411,541
Open	0.0610
Previous Close	0.0610
Day's Range	0.0610 - 0.0620
52-Week Range	0.0260 - 0.0860
Beta	0.07
RSI	48.84
Earnings Date	May 26, 2026

About Control Bionics

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyogr...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CBL

Financial Performance

In fiscal year 2025, Control Bionics's revenue was 6.14 million, an increase of 14.84% compared to the previous year's 5.35 million. Losses were -6.11 million, 3.30% more than in 2024.